Psyence Biomedical Signs Manufacturing Services Agreement With DEA-Registered Benuvia For Planned U.S. Manufacture Of Pharmaceutical-Grade Ibogaine Active Pharmaceutical Ingredient

Psyence Biomedical has signed a manufacturing services agreement with Benuvia, which operates a DEA-registered facility in Texas, to produce pharmaceutical-grade ibogaine. This partnership aims to establish U.S. manufacturing capabilities for ibogaine, aligning with Psyence's strategy to create an integrated supply and regulatory development platform through TIRC. The agreement supports TIRC's exclusive access to PsyLabs' ibogaine as outlined in a previous term sheet.